Mitch Dowsett mainly focuses on Internal medicine, Breast cancer, Oncology, Tamoxifen and Gynecology. His study brings together the fields of Endocrinology and Internal medicine. His Breast cancer study combines topics from a wide range of disciplines, such as Clinical trial, Estrogen and Chemotherapy.
His Oncology research is multidisciplinary, relying on both Proportional hazards model, Randomized controlled trial, Surgery, Hazard ratio and Adjuvant therapy. The Tamoxifen study combines topics in areas such as Hormonal therapy, Adjuvant and Drug resistance. His work carried out in the field of Gynecology brings together such families of science as Odds ratio, Guideline, Placebo, Oncotype DX and Prospective cohort study.
His main research concerns Internal medicine, Breast cancer, Oncology, Endocrinology and Tamoxifen. His Internal medicine research focuses on Aromatase, Estrogen receptor, Anastrozole, Estrogen and Aromatase inhibitor. As a member of one scientific family, Mitch Dowsett mostly works in the field of Breast cancer, focusing on Gynecology and, on occasion, Placebo.
The concepts of his Oncology study are interwoven with issues in Clinical trial, Chemotherapy, Randomized controlled trial, Proportional hazards model and Hazard ratio. His study in Endocrinology focuses on Hormone, Sex hormone-binding globulin, Estrone, Testosterone and Body mass index. His research integrates issues of Oncotype DX, Pharmacology and Endocrine system in his study of Tamoxifen.
Mitch Dowsett focuses on Breast cancer, Internal medicine, Oncology, Cancer research and Tamoxifen. His research in Breast cancer intersects with topics in Pathology, Gene and Estrogen. His Internal medicine study combines topics in areas such as Endocrinology and Gene expression.
His Endocrinology research is multidisciplinary, incorporating perspectives in Prospective cohort study and GREB1. His work deals with themes such as Cancer, Chemotherapy, MEDLINE, Predictive value of tests and Oncotype DX, which intersect with Oncology. His Cancer research research includes elements of Mutation, Transactivation, Fulvestrant, Endocrine system and ErbB.
Mitch Dowsett mostly deals with Breast cancer, Internal medicine, Oncology, Chemotherapy and Hazard ratio. Breast cancer is a primary field of his research addressed under Cancer. Internal medicine is closely attributed to Gene in his work.
Mitch Dowsett combines subjects such as Neoadjuvant therapy, Oestrogen receptor, Palbociclib, Estrogen receptor and Biomarker with his study of Oncology. His study in Chemotherapy is interdisciplinary in nature, drawing from both Meta-analysis, Endocrine therapy, Disease and Discontinuation. As part of one scientific family, Mitch Dowsett deals mainly with the area of Hazard ratio, narrowing it down to issues related to the Cohort, and often Residual risk, Primary tumor and Interquartile range.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch.
The New England Journal of Medicine (2005)
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty.
Journal of Clinical Oncology (2006)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Antonio C Wolff;M Elizabeth Hale Hammond;Kimberly H Allison;Brittany E Harvey.
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond;Daniel F Hayes;Mitch Dowsett;D Craig Allred.
Journal of Clinical Oncology (2010)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C Davies;J Godwin;Richard Gray.
The Lancet (2011)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C. Wolff;M. Elizabeth H Hammond;David G. Hicks;Mitch Dowsett.
Archives of Pathology & Laboratory Medicine (2014)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume.
The Lancet (2007)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett;Torsten O. Nielsen;Roger A’Hern;John Bartlett.
Journal of the National Cancer Institute (2011)
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.
T J Key;P N Appleby;G K Reeves;A Roddam.
Journal of the National Cancer Institute (2003)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick;Ivana Sestak;Michael Baum;Aman U Buzdar.
Lancet Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: